Accordingly, previous studies performed in patients with AD have documented that an increase in CSF orexin-A levels is correlated with the degree of cognitive impairment and the concomitant presence of neuropsychiatric symptoms, sleep impairment, and sleep-wake cycle misalignment [9–10, 38, 39, 40]. The gene discussed is HCRT; the disease is Cognitive impairment.